These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 23427297

  • 1. Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growth.
    Ponnurangam S, Standing D, Rangarajan P, Subramaniam D.
    Mol Cancer Ther; 2013 May; 12(5):598-609. PubMed ID: 23427297
    [Abstract] [Full Text] [Related]

  • 2. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
    Subramaniam D, Periyasamy G, Ponnurangam S, Chakrabarti D, Sugumar A, Padigaru M, Weir SJ, Balakrishnan A, Sharma S, Anant S.
    Mol Cancer Ther; 2012 Jul; 11(7):1598-608. PubMed ID: 22532602
    [Abstract] [Full Text] [Related]

  • 3. Tunicamycin inhibits colon carcinoma growth and aggressiveness via modulation of the ERK-JNK-mediated AKT/mTOR signaling pathway.
    You S, Li W, Guan Y.
    Mol Med Rep; 2018 Mar; 17(3):4203-4212. PubMed ID: 29344654
    [Abstract] [Full Text] [Related]

  • 4. A new discovery: Total Bupleurum saponin extracts can inhibit the proliferation and induce apoptosis of colon cancer cells by regulating the PI3K/Akt/mTOR pathway.
    Zhang X, Liu Z, Chen S, Li H, Dong L, Fu X.
    J Ethnopharmacol; 2022 Jan 30; 283():114742. PubMed ID: 34655668
    [Abstract] [Full Text] [Related]

  • 5. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
    Leu WJ, Swain ShP, Chan SH, Hsu JL, Liu SP, Chan ML, Yu CC, Hsu LC, Chou YL, Chang WL, Hou DR, Guh JH.
    Oncotarget; 2016 Nov 22; 7(47):76995-77009. PubMed ID: 27769069
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
    Yuan CX, Zhou ZW, Yang YX, He ZX, Zhang X, Wang D, Yang T, Pan SY, Chen XW, Zhou SF.
    Drug Des Devel Ther; 2015 Nov 22; 9():1293-318. PubMed ID: 25767376
    [Abstract] [Full Text] [Related]

  • 10. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

  • 11. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.
    Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y, Kwiatkowski NP, Wang J, Westover KD, Gao P, Ercan D, Niepel M, Thoreen CC, Kang SA, Patricelli MP, Wang Y, Tupper T, Altabef A, Kawamura H, Held KD, Chou DM, Elledge SJ, Janne PA, Wong KK, Sabatini DM, Gray NS.
    Cancer Res; 2013 Apr 15; 73(8):2574-86. PubMed ID: 23436801
    [Abstract] [Full Text] [Related]

  • 12. The anti-esophageal cancer cell activity by a novel tyrosine/phosphoinositide kinase inhibitor PP121.
    Peng Y, Zhou Y, Cheng L, Hu D, Zhou X, Wang Z, Xie C, Zhou F.
    Biochem Biophys Res Commun; 2015 Sep 11; 465(1):137-44. PubMed ID: 26235881
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH, Choi MJ, Hong S, Lee H, Hong SW, Zheng HM, Lee HS, Hong S, Hong SS.
    Cancer Lett; 2012 Mar 28; 316(2):187-95. PubMed ID: 22182943
    [Abstract] [Full Text] [Related]

  • 15. Oxymatrine synergistically enhances antitumor activity of oxaliplatin in colon carcinoma through PI3K/AKT/mTOR pathway.
    Liu Y, Bi T, Wang Z, Wu G, Qian L, Gao Q, Shen G.
    Apoptosis; 2016 Dec 28; 21(12):1398-1407. PubMed ID: 27671687
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.
    Xu S, Li S, Guo Z, Luo J, Ellis MJ, Ma CX.
    Mol Cancer Ther; 2013 Aug 28; 12(8):1665-75. PubMed ID: 23689832
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of aldose reductase prevents growth factor-induced G1-S phase transition through the AKT/phosphoinositide 3-kinase/E2F-1 pathway in human colon cancer cells.
    Ramana KV, Tammali R, Srivastava SK.
    Mol Cancer Ther; 2010 Apr 28; 9(4):813-24. PubMed ID: 20354121
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.